EUVIMEDEUVIMED entdecken
Open Access

Myocarditis in Patients Starting Combination Checkpoint Inhibitor Therapy: Analysis of a Commercial Claims Database

Alistair C Lindsay, Alexander M Walker iD, Sebastian Schneeweiss iD

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.035689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Alistair C Lindsay und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital, Harvard Medical School Boston MA. Hauptthemen laut MEDLINE: Myocarditis, Immune Checkpoint Inhibitors, Nivolumab, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors have improved the clinical outcomes of several cancers but have also been associated with a greater risk of immune‐related adverse effects, especially when combined. The objective of this study was to investigate the incidence of myocarditis in relation to the use of dual concurrent versus single immune checkpoint inhibitors therapies. Methods and Results A cohort study was conducted using medical and pharmacy claims data (2011–2022) from a large US commercial insurer. Cox regression quantified the comparative risks of myocarditis or heart failure in patients with cancer receiving treatment with combination therapy (nivolumab and ipilimumab) in comparison to taking a single immune checkpoint inhibitor only. Mean follow‐up time in 53 018 patients was 226 days (interquartile range, 93–495 days). There were 148 cases of myocarditis (0.3%), 33 (0.7%) in patients on combination therapy, and 115 (0.2%) in patients on monotherapy. The risk of myocarditis per 1000 patients was 7.40 in the combination therapy group and 2.37 in the monotherapy group (risk ratio, 3.12 [95% CI, 2.12–4.60]). Using multivariable regression analysis, the hazard ratio for myocarditis in the combination therapy group was 2.38 (1.57–3.63). No difference in the risk of heart failure was found between combination and single therapy.

Conclusions

Therapy with 2 immune checkpoint inhibitors was associated with an increased risk of myocarditis compared with monotherapy, with most cases occurring in the first 6 months of therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisImmune Checkpoint InhibitorsNivolumabNeoplasmsIpilimumabHumansMaleFemaleMiddle AgedIncidenceUnited StatesDatabases, FactualRetrospective StudiesAdultAgedAntineoplastic Combined Chemotherapy ProtocolsRisk FactorsHeart FailureRisk AssessmentTime Factors

Stichwörter der Autor:innen

cardio‐oncologycheckpoint inhibitorheart failuremyocarditisreal‐world evidence

Substanzen

Immune Checkpoint InhibitorsNivolumabIpilimumab

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital, Harvard Medical School Boston MA.
  • Department of Epidemiology Harvard T.H. Chan School of Public Health Boston MA.

ORCID-Profile: Alexander M Walker, Sebastian Schneeweiss

Förderung

  • NIAMS NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Lindsay, A. C., Walker, A. M., & Schneeweiss, S. (2025). Myocarditis in Patients Starting Combination Checkpoint Inhibitor Therapy: Analysis of a Commercial Claims Database. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.035689

Vancouver

Lindsay AC, Walker AM, Schneeweiss S. Myocarditis in Patients Starting Combination Checkpoint Inhibitor Therapy: Analysis of a Commercial Claims Database. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.035689

BibTeX
@article{Lindsay2025,
  author = {Lindsay, Alistair C and Walker, Alexander M and Schneeweiss, Sebastian},
  title = {Myocarditis in Patients Starting Combination Checkpoint Inhibitor Therapy: Analysis of a Commercial Claims Database},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.035689}
}
Kostenlos starten →